PT  - JOURNAL ARTICLE
AU  - Gutierrez, Juan Pablo
AU  - Bertozzi, Stefano M.
TI  - Non-communicable diseases and inequalities increase risk of death among COVID-19 patients in Mexico
AID  - 10.1101/2020.05.27.20115204
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.27.20115204
4099  - http://medrxiv.org/content/early/2020/05/29/2020.05.27.20115204.short
4100  - http://medrxiv.org/content/early/2020/05/29/2020.05.27.20115204.full
AB  - Background Current SARS-CoV-2 pandemic is confronting Mexico with pre-existing challenges: epidemic of non-communicable diseases (NCD) and high social inequity. Those challenges may worsen burden of COVID-19.Methods and findings Using data from national reporting of SARS-CoV-2 tested individuals, we analyzed those with a positive result to estimated odds of hospitalization, intubation and death based on pre-existing non-communicable diseases and socioeconomic indicators. We found that obesity, diabetes and hypertension increase the odds of the 3 outcomes, as well as indicators of social vulnerability.Conclusions Mexico’s response to COVID-19 is stymied by a synergistic double challenge: raging NCDs and extreme social inequity. The response to the current pandemic must take both of them into account both to be effective and to ensure that the burden of COVID-19 not fall disproportionately on those who are already disadvantaged.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this analysisAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This a secondary analysis of a public available datasetAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this analysis are available at https://www.gob.mx/salud/documentos/datos-abiertos-152127 https://www.gob.mx/salud/documentos/datos-abiertos-152127